BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nexiguran ziclumeran readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nexiguran ziclumeran\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06672237-11313@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nexiguran ziclumeran: Phase 3 readout est. (NCT06672237)
DESCRIPTION:Nexiguran ziclumeran\, phase 3.\nStudy: A Phase 3 Study of NTLA
 -2001 in ATTRv-PN\nEstimated primary completion: July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06672237
URL:https://assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128629-11313@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nexiguran ziclumeran: Phase 3 readout est. (NCT06128629)
DESCRIPTION:Nexiguran ziclumeran\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: MAGNITUDE: A Phase 3 Study of NTLA-2001 in Partic
 ipants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06128629
URL:https://assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
